News Column

Cellectis Awards genOway an Exclusive Sublicense for Its Homologous Recombination Technology in the Field of Genetically Modified Rodent Models

February 7, 2014

Cellectis, a genome engineering specialist, and genOway, an animal model specialist, announce an exclusive agreement under which genOway becomes the exclusive provider of Cellectis' homologous recombination technology for research applications in genetically modified rodents.

According to a release, Cellectis will remain the partner for any other applications such as bioproduction and therapeutics. Financial conditions were not disclosed.

genOway is recognized by the industry as a company focusing on high-value research models for candidate drug evaluation. Over the past few years, genOway has developed methods for generating innovative approaches, which combine exclusive technologies - Internal Ribosome Entry Site (IRES), Recombinase Mediated Cassette Exchange (RMCE), Tetracycline, etc, with proprietary technologies (QuickKin, 2in1, etc), proprietary software and expertise.

"We are very happy with this exclusive partnership with Cellectis. Both teams have worked intensively on this agreement, taking the market needs into account. This complete and exclusive agreement is the solution the market was waiting for," said Alexandre Fraichard, genOway CEO. "Access to this technology enables us to complete our portfolio of exclusive technologies and solutions and to guarantee our customers that we'll provide them with a research model which exactly fits their needs."

"Other transgenic companies and internal facilities only provide them with a model they can develop," added Alexandre Fraichard. "We are the only transgenic company providing a guaranteed freedom to operate. It is essential for industrial researchers, and increasingly for leading academic centers, to guarantee that they have the freedom to use their models. This is the only way to secure their future rights to results. By providing both the technologies and the freedom to operate, genOway has become the only relevant partner for rodent models."

"The collaboration between genOway and Cellectis fits within our mission to enable scientists to access our technologies," said Andre Choulika, Cellectis' Chairman and CEO. "This new agreement with genOway is a major step forward in our strategy. genOway is the best exclusive partner for the research rodent model arena. The Company's focus is on allogeneic cancer immunotherapy using TALENTM engineered T-Cell together with Chimeric Antigen Receptor (CAR) for liquid tumors."

This agreement will enable genOway to exclusively provide academic and industry scientists with complete secure access to Cellectis' homologous recombination technology for use in rodent models.

More information:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Professional Services Close - Up

Story Tools